

DOCTORAL THESIS

Total Synthesis and Structural Modification of Plant Natural Products Ardisiphenol D and Napabucasin as Anticancer Lead Compounds

CHIK, Wai I

Date of Award:
2021

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

ABSTRACT

Nature is a vast treasure for humans. Numerous cytotoxic phytochemicals have been derived as lead compounds for the discovery of novel chemotherapeutics over the years. However, chemotherapy resistance is common, particularly in cancer stem cells (CSCs) due to their self-renewal nature, and thus the search for novel anticancer agents must be continued.

In our continuing drug discovery programme, napabucasin has been isolated from the roots of *Radermachera boniana* Dop. (Bignoniaceae). Napabucasin was found to bypass the resistance problem against ordinary chemo- and radio-cancer therapies by selectively targeting cancer stem cells and metastasis, and therefore considered a new generation lead compound for preventing cancer relapse and metastasis. Structural modifications of napabucasin have been attempted but the study on its *N*-heterocyclic analogues is limited despite the fact that nitrogen-based heterocyclic compounds comprise the largest proportion among all the other heterocycles in the U.S. Food and Drug Administration (FDA) approved anticancer small molecules. More potent candidates have been suggested in several studies, but their research have not been extended to cancer stem cells.

In the present study, total synthetic routes for obtaining napabucasin (**Scheme 1**) and a series of nitrogen-based analogues (**Scheme 2**) mimicking the chemical structure of napabucasin have been established. The synthesized compounds have been subjected to tumorsphere formation assays in HCT116 human colon cancer derived CSCs. Napabucasin significantly inhibited sphere formation at 0.5 μM and even induced cell death of HCT116 cancer stem cells at higher dosage i.e. 1 μM . Interestingly, the nitrogen counterpart demonstrated no obvious effect in the assay even at high concentration of 5 μM . However, the inhibitory effect on cancer stem cell's sphere formation ability has been rescued in the synthesized analogue **A120**, which has a simpler structure and improved solubility. Sphere formation of cancer stem cells has been retarded upon treatment of 0.6 μM of **A120**, while 1.2 μM of the compound could induce cell death. The differential inhibitory effects of the chemically diversified compounds on cancer stem cells in our studies revealed that the oxygen atom in the heterocyclic ring system may act as a hydrogen bond acceptor in the interaction with its binding target (**Figure 7 – 8**).

On the other hand, bioactivity-guided fractionation and isolation of the active extracts of the roots of *Ardisia lindleyana* also led to the identification of ardisiphenol D in our drug discovery programme. The research on this type of compounds has been limited. Synthetic studies have barely been touched and the functional and structural requirements of the compound have not been reported so far. Extensive studies on structural modification, structure-activity relationship elucidation, target binding and lead optimization are crucial for the development of this type of compounds into clinically potent drug candidates.

In the present study, the first total synthesis of ardisiphenol D has been accomplished for a more economical and environmentally friendly approach of obtaining the natural compound (**Scheme 8**). The total synthesis route has also been optimized with fewer steps and can be applied in obtaining some of its analogues (**Scheme 13**). By several synthetic approaches as well as functional group interconversions (**Figure 17**), a total of 135 derivatives with rich chemical and structural diversity have been synthesized. Structure-activity relationship analysis of the derivatives (**Figure 18**), categorized into different classes according to the characteristic functional group constituents, has been conducted following *in vitro* SRB antiproliferation assay against a human colorectal cancer cell line. The acetyl group at C-4 or C-1 is determined to be crucial to the anticancer potency of this type of phenolic compounds, while the formation of an additional acyl group could enhance the activity. Compound **ad4** has demonstrated improved *in vitro* and *in vivo* antineoplastic effects, with reduced toxicity. Upon treatment of HCT116 human colorectal cancer cell induced tumour in nude mice by intraperitoneal administration of **ad4** at 10 mg/kg, the tumour suppression rate reached 56 %, which outperformed the mainstay colorectal cancer remedy 5-FU at 25 mg/kg.

More synthetic and mechanistic studies of napaubasin and ardisiphenol D, and their related derivatives have to be done in the future to transform the compounds into drug candidates to overcome chemotherapy resistance and metastasis.

Keywords: Phytochemicals, anticancer, cancer stem cells, napabucasin, ardisiphenol D, total synthesis, structural modification, SAR analysis.

TABLE OF CONTENTS

DECLARATION.....	i
ABSTRACT.....	ii
ACKNOWLEDGEMENTS	iv
TABLE OF CONTENTS	v
LIST OF TABLES	ix
LIST OF FIGURES	xiv
LIST OF SCHEMES	xvi
List of Abbreviations	xviii
PART I Total synthesis and structural modifications of napabucasin (BBI608) for targeting cancer stem cells	1
Chapter 1. A literature review on the use of naphthoquinones and furano-naphthoquinones as anti-invasive and anti-cancer stem cell agents.....	2
Prevalence of cancer and metastasis	3
Quinones – an important class of FDA approved small molecule-based anticancer agents	7
Napabucasin (BBI608) as a natural anti-cancer stem cell agent and STAT 3 inhibitor	48
Chapter 2. Total synthesis of napabucasin (BBI608) and structural modifications.....	50
Introduction.....	51

Napabucasin as a natural anticancer stem cell agent and potential new generation lead compound for preventing cancer relapse and metastasis.....	51
Recent research progress on total synthesis and lead optimization of napabucasin	53
Objectives.....	56
Results and Discussions	58
1. Total synthesis route for napabucasin has been accomplished	58
2. Synthetic napabucasin showed similar in vitro anticancer activity as the natural compound	58
3. Total synthesis route for <i>N</i> -heterocyclic analogue of napabucasin has been established	59
4. Loss of activity in <i>N</i> -heterocyclic analogue of napabucasin against HCT116 cells and cancer stem cells in the sphere formation assay	61
5. Methylation was attempted to disrupt the intramolecular hydrogen bond, but it failed to reverse the loss of activity	64
6. A series of novel <i>N</i> -heterocyclic structural analogues of napabucasin have been synthesized.....	64
7. Nitrogen heterocyclic analogues with side chain modification showed significant enhancement in solubility but the loss of cytotoxicity was not reversed.	73
8. The loss of activity in the <i>N</i> -heterocyclic analogues may be caused by the absence of the extra lone pair of electrons.	73
9. The inhibitory effect on cancer stem cell's sphere formation ability has been rescued in A120 , which has a simpler structure and improved solubility.	74
Materials and Methods.....	75
Conclusions.....	81
Future Perspectives.....	82

PART II Total synthesis and derivatizations of a natural anticancer agent Ardisiphenol

D 83

Chapter 3. First total synthesis of ardisiphenol D 84

Introduction..... 85

Objectives..... 86

Results and Discussions 87

1. Retrosynthetic analysis of ardisiphenol D has been performed 87

2. The first total synthesis route of ardisiphenol D has been established..... 87

3. The structure of the synthesized ardisiphenol D has been confirmed..... 93

4. The total synthesis route of ardisiphenol D has been optimized..... 94

Conclusions..... 99

Chapter 4. Structural modifications and biological evaluations of ardisiphenol D..... 100

Introduction..... 101

Objectives..... 101

Results and Discussions 103

1. Design and synthetic approach for furnishing ardisiphenol D-related derivatives 103

2. Synthesis of different series of ardisiphenol D-related derivatives by functional group interconversions..... 107

3. In vitro cytotoxicity screening of selected compounds..... 175

4. Structure-activity relationship analysis of ardisiphenol D 180

5. In vivo study of ardisiphenol D and its synthetic congener 4-acetoxy-3-methoxy-5-tridecylphenyl cyclopropanecarboxylate (**ad4**) in xenograft mouse model 186

Materials and Methods..... 189

Conclusions.....	201
Future perspectives.....	202
Chapter 5. Conclusions and future perspectives.....	203
Conclusions.....	204
Future perspectives.....	215
Publications	346
Conference presentations	346
References.....	347
CURRICULUM VITAE.....	372

LIST OF TABLES

Table 1 FDA approved cytotoxic small molecules for targeting cancer since 1950.....	8
Table 2 Anti-invasive mechanisms of naphthoquinones.....	28
Table 3 ¹ H NMR spectral data of napabucasin being synthesized in the present study and reported in literature.....	59
Table 4 ¹ H NMR Spectral data (400 MHz) of analogues 19 – 21	65
Table 5 ¹ H NMR Spectral data (400 MHz) of analogues 19a – 19e	66
Table 6 ¹ H NMR Spectral data (400 MHz) of analogues 19f – 19h	67
Table 7 ¹ H NMR Spectral data (400 MHz) of analogues 21a – 21c	68
Table 8 ¹ H NMR Spectral data (400 MHz) of analogues 21d – 21e	69
Table 9 ¹ H NMR Spectral data (400 MHz) of analogue 22	70
Table 10 ¹³ C NMR Spectral data (100 MHz) of analogues 19a – 19h	71
Table 11 ¹³ C NMR Spectral Data (100 MHz) of analogues 21, 21a – 21e	72
Table 12 Different reaction conditions attempted for the conversion of Br to OH in the synthesis of ardisiphenol D.....	89
Table 13 Reaction conditions that the protecting groups had to withstand.	91
Table 14 ¹ H NMR Spectral data (400 MHz) of ardisiphenol D.....	93
Table 15 ¹³ C NMR Spectral data (100 MHz) of intermediates of ardisiphenol D.....	94
Table 16 Ardisiphenol D derivatives to be classified according to their structures.....	113
Table 17 ¹ H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in aa class.	124
Table 18 ¹³ C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in aa class.	124
Table 19 ¹ H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ab class.	125

Table 20 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ab class (cont'd).	126
Table 21 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ab class.	127
Table 22 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ab class (cont'd).	128
Table 23 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ac class.	129
Table 24 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ac class.	130
Table 25 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ac class (cont'd).	131
Table 26 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ad class.	132
Table 27 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ad class.	133
Table 28 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ad class (cont'd).	134
Table 29 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ba class.	135
Table 30 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ba class.	135
Table 31 ^1H NMR spectral data (CDCl_3 , 400 MHz) of ardisiphenol D and derivatives in bd class.	136
Table 32 ^1H NMR spectral data (CDCl_3 , 400 MHz) of ardisiphenol D and derivatives in bd class (cont'd).	137
Table 33 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in bd class.	138
Table 34 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in bd class (cont'd).	139

Table 35 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in bd class (cont'd).	140
Table 36 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in bx class.....	141
Table 37 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in bx class.....	142
Table 38 ^1H NMR spectral data (400 MHz) of ardisiphenol D- related derivatives (CDCl_3) in ca class.....	143
Table 39 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D-related derivatives in ca class.	144
Table 40 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D-related derivatives in ca class (cont'd).....	145
Table 41 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in cc class.....	146
Table 42 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in cc class.....	147
Table 43 ^1H NMR spectral data (CDCl_3 , 400 MHz) of ardisiphenol D and derivatives in da class.	148
Table 44 ^{13}C NMR spectral data (CDCl_3 , 100 MHz) of ardisiphenol D and derivatives in da class.	148
Table 45 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in db class.....	149
Table 46 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in db class.....	150
Table 47 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in db class (cont'd).	151
Table 48 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in dd class.....	152
Table 49 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in dd class.....	153
Table 50 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in dd class (cont'd).	154

Table 51 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ea class.	155
Table 52 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ea class.	156
Table 53 ^1H NMR spectral data (CDCl_3 , 400 MHz) of ardisiphenol D and derivatives in eb class.	157
Table 54 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in eb class.	158
Table 55 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in eb class (cont'd).	159
Table 56 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ec class.....	160
Table 57 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ec class.....	161
Table 58 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ed class.	162
Table 59 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ed class (cont'd).	163
Table 60 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ed class (cont'd).	164
Table 61 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ed class.	165
Table 62 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ed class (cont'd).	166
Table 63 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ed class (cont'd).	167
Table 64 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ef class.	168
Table 65 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ef class.	169
Table 66 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in eh class.	170

Table 67 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in eh class (cont'd).	171
Table 68 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in eh class (cont'd).	172
Table 69 ^1H NMR spectral data (400 MHz) of ardisiphenol D and derivatives in ex class (cont'd).	173
Table 70 ^{13}C NMR spectral data (100 MHz) of ardisiphenol D and derivatives in ex class.	174
Table 71 Cytotoxicity evaluation of ardisiphenol D and the synthesized analogues.	175
Table 72 Anticancer potencies of different classes of ardisiphenol D-related derivatives.	182
Table 73 Treatment groups in xenograft mice model experiment.	200

LIST OF FIGURES

Figure 1 Redox cycling of quinones.	7
Figure 2 The skeletons of naphthoquinones, furano-naphthoquinones and their analogues.	21
Figure 3 The chemical structures of anti-invasive naphthoquinones.	27
Figure 4 Retrosynthetic analysis of the reported approaches of synthesizing napabucasin.	53
Figure 5 Inhibition of sphere formation of HCT116 cancer stem cells in treatment with a) DMSO b) napabucasin c) 21 at different concentrations.	62
Figure 6 Inhibition of sphere formation of HCT116 cancer stem cells in treatment with a) 19 b) 19c c) 19h d) A120 at different concentrations.	63
Figure 7 The structure of napabucasin and its <i>N</i> -heterocyclic analogue a) 2D structure of a) napabucasin b) 2D structure of analogue 21 c) predicted 3D structure of napabucasin d) predicted 3D structure of 21	74
Figure 8 The structure of A120 a) 2D structure b) predicted 3D structure.	75
Figure 9 Structure of ardisiphenol D.	85
Figure 10 Oxidation of hydroquinone form of ardisiphenol D to its benzoquinone form.	86
Figure 11 Structural analysis of ardisiphenol D.	87
Figure 12 Possible sites for structural modifications of ardisiphenol D.	101
Figure 13 Key precursor for synthesis of C-4 functionalized compounds.	104
Figure 14 Key precursor for synthesis of C-1 functionalized compounds.	104
Figure 15 Key precursors for synthesis of C-6 functionalized compounds.	104
Figure 16 Number of derivatives of ardisiphenol D being synthesized in each category.	107
Figure 17 Functional group transformations based on ab class of compounds.	108
Figure 18 Functional group transformations based on ba class of compounds.	109

Figure 19 Functional group transformations based on eb class of compounds.	110
Figure 20 Functional group transformations based on ef class of compounds.	111
Figure 21 'Synthetic pathways' of ardisphenol D based derivatives.	112
Figure 22 Preliminary structure-activity relationship (SAR) analysis of ardisphenol D derivatives.	185
Figure 23 <i>In vivo</i> toxicities of ardisiphenol D and ad4 in HCT116 xenograft mice.	186
Figure 24 Inhibition of tumor growth by ad4 as compared to 5-FU (positive control).	187
Figure 25 The structure of napabucasin and its <i>N</i> -heterocyclic analogue a) 2D structure of napabucasin b) 2D structure of analogue 21 c) predicted 3D structure of napabucasin d) predicted 3D structure of 21	208
Figure 26 The structure of A120 a) 2D structure b) predicted 3D structure.	208
Figure 27 'Synthetic pathways' of ardisphenol D based derivatives.	213
Figure 28 Preliminary structure-activity relationship (SAR) analysis of ardisphenol D derivatives.	214
Figure 29 Structure of the synthetic analogue of ardisphenol D ad4	214

LIST OF SCHEMES

Scheme 1 Total synthesis route of napabucasin.	60
Scheme 2 Total synthesis route of nitrogen-heterocyclic analogue of napabucasin and its derivatives.	60
Scheme 3 Methylation of the secondary amine on nitrogen-heterocyclic analogue of napabucasin.	64
Scheme 4 Retrosynthetic analysis of ardisiphenol D.	87
Scheme 5 Conversion of aryl bromide to phenol via boronic acid.	88
Scheme 6 Conversion of aryl bromide to phenol via Dakin oxidation.	89
Scheme 7 Conversion of aryl bromide to TMS masked phenol.	89
Scheme 8 First total synthesis of ardisiphenol D (route 1).	92
Scheme 9 Total synthesis of ardisiphenol D (route 2).	96
Scheme 10 Total synthesis of ardisiphenol D (route 3).	96
Scheme 11 Total synthesis of ardisiphenol D (route 4).	97
Scheme 12 Total synthesis of ardisiphenol D (route 5).	98
Scheme 13 Total synthesis of ardisiphenol D (route 6).	98
Scheme 14 Synthesis of the key precursor in Figure 11	104
Scheme 15 Synthesis of key precursor in Figure 12	105
Scheme 16 Synthesis of the other key precursor in Figure 12	105
Scheme 17 Synthesis of C-6 functionalized derivatives using the synthesized precursor (route 1).	105
Scheme 18 Synthesis of C-6 functionalized derivatives using the synthesized precursor (route 2).	105

Scheme 19 Total synthesis for the C-2 functionalized derivatives.	106
Scheme 20 Total synthesis route of napabucasin.	207
Scheme 21 Total synthesis route of nitrogen-heterocyclic analogue of napabucasin and its derivatives.	207
Scheme 22 First total synthesis of ardisiphenol D.	211
Scheme 23 Optimized total synthesis of ardisiphenol D.	212